Cargando…
Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy
BACKGROUND: To assess the influence of molecular markers with potential prognostic value to groups of patients with newly diagnosed glioblastoma patients were examined: group A with 36 patients (surgical resection plus standard combined chemoradiotherapy) and group B with 36 patients (surgical resec...
Autores principales: | Urbschat, Steffi, Sippl, Christoph, Engelhardt, Jana, Kammers, Kai, Oertel, Joachim, Ketter, Ralf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418867/ https://www.ncbi.nlm.nih.gov/pubmed/28484518 http://dx.doi.org/10.1186/s13039-017-0317-5 |
Ejemplares similares
-
RB1‑promoter methylation in glioblastoma: A rare event in glioblastoma
por: Urbschat, Steffi, et al.
Publicado: (2023) -
Is Interstitial Chemotherapy with Carmustine (BCNU) Wafers Effective against Local Recurrence of Glioblastoma? A Pharmacokinetic Study by Measurement of BCNU in the Tumor Resection Cavity
por: Ohnishi, Takanori, et al.
Publicado: (2022) -
Promoter methylation of RB1, P15, P16, and MGMT and their impact on the clinical course of pilocytic astrocytomas
por: Sippl, Christoph, et al.
Publicado: (2018) -
Molecular Biological Determinations of Meningioma Progression and Recurrence
por: Linsler, Stefan, et al.
Publicado: (2014) -
Deletions in the 17q chromosomal region and their influence on the clonal cytogenetic evolution of recurrent meningiomas
por: Hemmer, Sina, et al.
Publicado: (2019)